CBDV: The Cannabinoid in Trials for Autism and Epilepsy
Cannabidivarin (CBDV) is a non-intoxicating cannabinoid studied for epilepsy and autism. Here's the honest science, including the trials that fell short.
Latest cannabis research findings, clinical studies, and scientific breakthroughs in cannabinoid medicine and plant science.
306 articles · page 9 of 13
Cannabidivarin (CBDV) is a non-intoxicating cannabinoid studied for epilepsy and autism. Here's the honest science, including the trials that fell short.
The lazy, dumb stoner is a myth built on bad data. Here is what large cohort studies and twin research actually show about cannabis, IQ, and drive.
The runner's high isn't endorphins. New research points to your own endocannabinoids—the same system cannabis acts on. Here's the revised science.
The endocannabinoidome (eCBome) expands the classic ECS into 100+ mediators, 20+ receptors, and 50+ enzymes. Here's why it changes everything.
Why most edibles take an hour to kick in, and how nano THC and live-rosin gummies actually speed up onset to 15-30 minutes. Hype vs. real science.
Does flushing cannabis before harvest work? A 2025 HortScience study and a blind-panel trial found no gain in THC, terpenes, flavor, or smoothness.
HHC vs THCP: one is hydrogenated and stable, the other binds CB1 33x tighter than THC. Professor High breaks down potency, legality, and safety.
Phytol and sabinene are minor cannabis terpenes with intriguing preclinical research on calm, inflammation, and the entourage effect. The honest science.
Most aromatic terpenes burn off before you inhale them. Here is the science on how little actually reaches your bloodstream and brain.
Triploid cannabis carries three chromosome sets instead of two, making it nearly seedless. Here's how it's bred and what the science actually shows.
Acetylated cannabinoids like THC-O release ketene — a documented severe lung toxin — when vaped. The 2026 chemistry paper everyone selling them ignored.
A 2026 study found CBC and CBG with silver nanoparticles killed MRSA 64x more effectively than silver alone — with zero resistance development. The science.
A 2026 cohort of 300,000+ patients found cannabis use disorder linked to 3.87x higher lung cancer risk. The data, the caveats, and what it means for users.
A 2026 scoping review of 28 RCTs across 12 DSM-5 conditions. Where cannabinoids show benefit, where evidence is thin, and what we still don't know.
Depressed patients widely use cannabis for sleep — and the science is nuanced. Real perceived benefit, real architecture concerns. What 2026 research shows.
A 2026 longitudinal study of 11,000+ youth shows THC exposure tracks with measurable brain trajectory changes — while CBD does not. The data parents need.
The first randomized trial of cannabis for acute migraine: vaporized THC+CBD flower beat placebo for pain freedom at 2 hours. What the science actually says.
Cell studies look at cannabis flavonoids, including cannflavin A, in inflammation assays. A benefit from a typical joint is still debated.
The UK Medical Cannabis Registry tracked 698 patients prescribed cannabis for depression. Mood, sleep, and anxiety all improved — with one important caveat.
Cannabis terpenes relieve pain via adenosine A2A receptors, not CB1/CB2 — with morphine-comparable analgesia. Why this rewrites the pain conversation.
A 2026 study: cannabis works better for chronic pain when it ALSO improves sleep, stress, and mood. Why multi-system effects matter — and how to use them.
A 2026 study found CBD reverses nicotine-induced glymphatic system damage in animal models. The neuroscience and the practical takeaway for vapers.
CBD has poor bioavailability — only 6-19% reaches your bloodstream. New nanoparticle research could change that, opening doors to stroke therapy.
A 2026 compliance study found 56% of hemp-derived THC retailers sold to underage-appearing buyers. What this means for parents, consumers, and the industry.
Related Topics
New guides and strain drops as they publish.
High IQ keeps the record: what you bought, how it hit, what to buy again.
High IQ: Cannabis Journal for iPhone opens to everyone soon.
Strain drops, terpene explainers, and the myths Professor High keeps killing.